Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company whose news flow is centered on its AI Nose SmellTech platform and related AI infrastructure, alongside development of its low-dose oral interferon candidate, VELDONA. Company updates frequently highlight progress in digitizing scent into Smell ID, expanding industrial deployments, and advancing its Smell Language Model (SLM) through its subsidiary ScentAI Inc.
On this page, readers can follow AIMD news related to industrial partnerships, commercialization milestones, and strategic agreements. Recent announcements have covered distribution and deployment partnerships in semiconductor front-end manufacturing, collaborations with industrial computing and edge AI providers, and expansion of AI Nose pilots across smart factories, robotics, and healthcare environments. Ainos also issues press releases on its GICS reclassification into the technology sector, intellectual property additions, and SmellTech-as-a-Service contracts.
Investors and observers can expect news items on topics such as multi-year SmellTech-as-a-Service agreements, pilot deployments in senior care and robotics, new patents for AI Nose and digital olfaction, and updates on the company’s platform strategy to separate sensing hardware (Ainos) from AI intelligence (ScentAI). Financial result releases and associated commentary provide additional context on research and development priorities and commercialization roadmaps.
By monitoring this news feed, users gain a consolidated view of how Ainos is building its SmellTech ecosystem across semiconductors, industrial automation, robotics, and healthcare, while continuing to develop its VELDONA oral interferon program. Bookmark this page for ongoing coverage of AIMD press releases, partnership announcements, and regulatory communications.
Ainos (NASDAQ:AIMD) outlined a phased deployment plan for up to 20,000 AI Nose systems, anchored by a confirmed initial order of 1,400 systems.
The initial order activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million, and the roadmap states potential annual order values approaching $10 million if fully executed, subject to staged technical validation and formal contractual conversion.
Validation testing is underway in advanced semiconductor front-end fabrication environments to support commercial integration and multi-site industrial scaling.
Ainos (NASDAQ:AIMD) activated a phased industrial deployment roadmap to install up to 20,000 AI Nose units in semiconductor production environments under a strategic framework with ASE Technology Holding.
Phase one includes a confirmed order of 1,400 units under a three-year subscription (~$2.1M), $350,000 in customer deposits, and a target completion by end of Q2 2026. Later phases (5,000 and up to 15,000 units) depend on milestone validation and contractual progression.
Ainos (NASDAQ:AIMD) reported statistically significant interim efficacy from its open-label VELDONA trial in feline chronic gingivostomatitis (FCGS). In six treated cats, mean oral inflammation improved ~38% at Week 6 and ~45% at Week 14, with 66.7% of subjects achieving ≥30% improvement.
Safety signals were absent: liver and renal labs remained stable and VELDONA was well tolerated. Enrollment continues to 12 subjects to assess dose response and durability.
Ainos (NASDAQ:AIMD) began live AI Nose deployments in semiconductor manufacturing after receiving an initial $2.1 million order from a back-end packaging and testing customer. Preparations in the second half of 2025 enabled on-site rollouts that started in January 2026.
Back-end deployments are now operating in live environments generating scent data, while front-end semiconductor pilots advance to broaden use cases and strengthen Ainos' Smell Language Model (SLM).
Ainos (NASDAQ:AIMD) announced a strategic partnership with Mirle to integrate its AI Nose SmellTech into Mirle's mobile and quadruped robotic platforms, extending deployments from commercial buildings into industrial environments such as semiconductor fabs and advanced manufacturing.
The collaboration aims to add chemical sensing to vision and audio, improve early detection of gas leaks and VOCs, and accelerate real-world data collection to scale the Smell ID library and platform capabilities.
Ainos (NASDAQ:AIMD) is advancing its AI Nose SmellTech platform, positioning scent as a native AI data layer through standardized Smell IDs and a proprietary Smell Language Model. The company reported multi-year semiconductor back-end orders of approximately $2.1M for ~1,400 AI Nose units and highlighted robotics partnerships to scale continuous scent data generation in 2026.
The firm's dual-engine architecture separates physical sensing from intelligence-as-a-service (via subsidiary ScentAI) to pursue recurring subscription economics, broader industrial deployments across front-end and back-end semiconductor operations, and accelerated data flywheel growth via robotics partnerships.
Ainos (NASDAQ:AIMD) announced a technology partnership with Mirle Automation on February 2, 2026, to integrate Ainos' AI Nose scent‑digitizing platform into mobile and quadruped robotic platforms.
The collaboration targets inspection, monitoring, and autonomous tasks — detecting VOCs, gas leaks, and chemical anomalies — to boost robotic situational awareness and safety across fabs, manufacturing, healthcare, outdoor inspection, and security applications.
Ainos (NASDAQ:AIMD / AIMDW) will participate in a fireside chat with Water Tower Research on Monday, January 26, 2026 at 11:00 a.m. ET.
The company will discuss its dual-engine SmellTech platform, partnership with Trusval Technology, progress scaling AI Nose technology toward commercial deployment, and strategic priorities for 2026. The event is listen-only and a replay will be posted under "Events" on Ainos' investor relations site.
Ainos (NASDAQ:AIMD) is advancing AI Nose from R&D toward scaled commercial deployment in 2026, supported by a dual-engine architecture separating hardware sensing and a software ScentAI layer. A three-year distribution and deployment agreement with Trusval Technology includes an initial minimum commitment of 600 AI Nose units, targeting front-end semiconductor wafer fabrication and broader manufacturing use cases. The structure aims to enable recurring, SaaS-style revenue through APIs, licensing, and subscriptions while expanded deployments feed a growing Smell ID library and machine-learning performance. Ainos relocated its U.S. headquarters to Houston, Texas in early 2026 to align with industrial and semiconductor ecosystems.
Ainos (NASDAQ:AIMD) announced a distribution and deployment agreement with Taiwan-based Trusval Technology on January 7, 2026 to expand AI Nose into semiconductor front-end manufacturing.
Under the contract, Trusval will be Ainos' authorized sales agent and deployment partner for front-end wafer fab applications, with an initial minimum purchase commitment of 600 AI Nose units to support real-world deployments and scent data accumulation in high-precision manufacturing environments.
The deal extends Ainos' SmellTech footprint upstream from back-end processes and aligns with the company's 2026 execution focus on disciplined, contract‑driven platform expansion.